Pulmonx (NASDAQ:LUNG) General Counsel Sells $17,498.91 in Stock

Pulmonx Corporation (NASDAQ:LUNG) General Counsel David Aaron Lehman sold 12,237 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $1.43, for a total transaction of $17,498.91. Following the transaction, the general counsel owned 240,755 shares of the company’s stock, valued at approximately $344,279.65. This trade represents a 4.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Pulmonx Stock Up 25.5%

NASDAQ LUNG opened at $2.02 on Friday. Pulmonx Corporation has a 12 month low of $1.31 and a 12 month high of $8.12. The company has a market capitalization of $83.33 million, a P/E ratio of -1.52 and a beta of 0.07. The company’s 50 day simple moving average is $1.75 and its 200 day simple moving average is $1.79. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.86 and a quick ratio of 4.15.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, March 4th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.14. The firm had revenue of $22.60 million during the quarter, compared to analysts’ expectations of $21.73 million. Pulmonx had a negative net margin of 59.67% and a negative return on equity of 78.35%. Equities research analysts expect that Pulmonx Corporation will post -1.55 earnings per share for the current fiscal year.

More Pulmonx News

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx beat Q4 expectations — EPS -$0.25 vs. consensus ~- $0.39 and revenue $22.6M vs. ~$21.7M; net loss narrowed and adjusted EBITDA improved year?over?year, signaling operational progress. Read More.
• Positive Sentiment: Closed a five?year senior secured credit facility with Perceptive Advisors (initial $40M draw; up to $60M total subject to milestones), which refinanced prior debt and extends maturities to 2031 — materially improves near?term liquidity. Read More.
• Positive Sentiment: Gross margin and cost discipline improved — Q4 gross margin ~78% and operating expenses down ~11% vs. prior year quarter, supporting a clearer path toward profitability if revenue momentum returns. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating (high target), which can attract momentum buyers given large upside vs. current levels. Read More.
• Neutral Sentiment: Management outlined a strategic restructuring and sales?force changes on the earnings call — intended to re?accelerate commercial growth but the near?term impact on procedure volumes is unclear. Read More.
• Neutral Sentiment: Some analysts updated targets (Canaccord trimmed its target but kept a Buy rating) — mixed analyst activity keeps coverage but shows differing views on recovery timing. Read More.
• Negative Sentiment: 2026 revenue guidance of $90M–$92M came in below consensus (~$94M), implying slower top?line growth and limiting near?term upside despite margin improvements. Read More.
• Negative Sentiment: Insider selling was reported (CEO, general counsel and other officers sold shares on March 2), which can increase perceived selling pressure and weigh on sentiment. Read More.
• Negative Sentiment: The new loan carries a high effective cost (SOFR + 7.0% with 3.75% floor and a 2% PIK option) and includes warrants — helpful for liquidity but increases interest burden and potential dilution if exercised. Read More.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on LUNG. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 target price on shares of Pulmonx in a research report on Thursday. Canaccord Genuity Group decreased their price target on Pulmonx from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Five analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pulmonx has a consensus rating of “Hold” and a consensus target price of $5.38.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of LUNG. Susquehanna Portfolio Strategies LLC acquired a new position in Pulmonx during the fourth quarter valued at $133,000. Engineers Gate Manager LP acquired a new stake in Pulmonx during the 4th quarter worth about $106,000. ADAR1 Capital Management LLC grew its stake in Pulmonx by 65.7% during the 4th quarter. ADAR1 Capital Management LLC now owns 355,410 shares of the company’s stock valued at $785,000 after acquiring an additional 140,913 shares in the last quarter. AQR Capital Management LLC grew its stake in Pulmonx by 144.6% during the 4th quarter. AQR Capital Management LLC now owns 58,919 shares of the company’s stock valued at $130,000 after acquiring an additional 34,828 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new position in shares of Pulmonx in the 4th quarter valued at about $31,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.